» Articles » PMID: 24046869

Apolipoprotein M Promotes Mobilization of Cellular Cholesterol in Vivo

Overview
Specialties Biochemistry
Biophysics
Date 2013 Sep 19
PMID 24046869
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The HDL associated apolipoprotein M (apoM) protects against experimental atherosclerosis but the mechanism is unknown. ApoM increases prebeta-HDL formation. We explored whether plasma apoM affects mobilization of cholesterol from peripheral cells in mice.

Methods And Results: ApoM-enriched HDL from apoM-transgenic mice increased the in vitro efflux of 3H-cholesterol from macrophages by 24 +/- 3% (p < 0.05) as compared with HDL from wild type (WT) mice, thus confirming previous findings. However, apoM-free HDL was not poorer than that of WT HDL to mobilize 3H-cholesterol. 3H-cholesterol-labeled foam cells were implanted in the peritoneal cavity of apoM-/-, WT and apoM-transgenic mice to assess the mobilization of cholesterol from foam cells in vivo and subsequent excretion into feces. The results showed a statistically non-significant trend towards increased mobilization of cellular cholesterol to plasma with increasing plasma apoM. However, the apoM-genotype did not affect the excretion of 3H-cholesterol in feces. Nevertheless, when apoM-/-, apoM-transgenic and WT mice received a constant intravenous infusion of 13C2-cholesterol/intralipid for 5 h, the rate of enrichment of blood free cholesterol with free 13C2-cholesterol was significantly lower (consistent with an increase in flux of unlabeled free cholesterol into the plasma) in the apoM-transgenic (3.0 +/- 0.9 per thousand/h) as compared to WT (5.7 +/- 0.9 per thousand/h, p < 0.05) and apoM-/- (6.5 +/- 0.6 per thousand/h, p < 0.01) mice.

Conclusion: The present data indicate that the plasma apoM levels modulate the ability of plasma to mobilize cellular cholesterol, whereas apoM has no major effect on the excretion of cholesterol into feces.

Citing Articles

Identification of Glomerular and Plasma Apolipoprotein M as Novel Biomarkers in Glomerular Disease.

Drexler Y, Molina J, Elfassy T, Ma R, Christoffersen C, Kurano M Kidney Int Rep. 2023; 8(4):884-897.

PMID: 37069998 PMC: 10105063. DOI: 10.1016/j.ekir.2023.01.031.


Gestational Hypertension and High-Density Lipoprotein Function: An Explorative Study in Overweight/Obese Women of the DALI Cohort.

Stadler J, van Poppel M, Christoffersen C, Hill D, Wadsack C, Simmons D Antioxidants (Basel). 2023; 12(1).

PMID: 36670930 PMC: 9854490. DOI: 10.3390/antiox12010068.


Changes in HDL cholesterol, particles, and function associate with pediatric COVID-19 severity.

Mietus-Snyder M, Suslovic W, Delaney M, Playford M, Ballout R, Barber J Front Cardiovasc Med. 2022; 9:1033660.

PMID: 36312284 PMC: 9597312. DOI: 10.3389/fcvm.2022.1033660.


The FoxOs are in the ApoM house.

Linton M, Yancey P, Leuthner Z, Brown J J Clin Invest. 2022; 132(7).

PMID: 35362476 PMC: 8970665. DOI: 10.1172/JCI158471.


HDL Composition, Heart Failure, and Its Comorbidities.

Diab A, Valenzuela Ripoll C, Guo Z, Javaheri A Front Cardiovasc Med. 2022; 9:846990.

PMID: 35350538 PMC: 8958020. DOI: 10.3389/fcvm.2022.846990.